3E3-14079-26408
4 vaccinations
0 coded responses
51 check-ins
0 free-text entries
0 call cases
- Sex
- Female
- Age at first dose
- 31-35
- ZIP prefix
- 430 / OH
- Registered
- 2021-02-20
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-02-20
Registered in v-safe
-
2021-02-20
Dose 1 — Pfizer-BioNTech
- 2021-02-20
- 2021-02-21
- 2021-02-22
- 2021-02-23
- 2021-02-24
- 2021-02-25
- 2021-02-26
- 2021-02-27
- 2021-03-06
-
2021-03-13
Dose 2 — Pfizer-BioNTech
- 2021-03-13
-
2021-03-14
Health check-in — days 1–6 daily, dose 2Feeling: Poor · Site: Pain · Fever · Chills, Muscle or body aches, Fatigue or tirednessAdult check-in
- 2021-03-15
- 2021-03-16
- 2021-03-17
- 2021-03-18
- 2021-03-19
- 2021-03-20
- 2021-03-27
- 2021-04-03
- 2021-04-10
- 2021-04-19
- 2021-04-24
- 2021-06-12
- 2021-09-11
-
2021-10-02
Dose 3 — Pfizer-BioNTech
- 2021-10-02
-
2021-10-03
Health check-in — days 1–6 daily, dose 3Feeling: Good · Site: Pain · Fever · Chills, Headache · Be unable to do your normal daily activitiesAdult check-in
- 2021-10-04
- 2021-10-05
- 2021-10-06
- 2021-10-07
- 2021-10-08
- 2021-10-09
- 2021-10-16
- 2021-10-23
- 2021-10-30
- 2021-11-06
- 2021-11-13
- 2022-01-01
- 2022-04-04
- 2022-10-02
-
2022-10-17
Dose 4 — Pfizer-BioNTechCo-administered: Flu
- 2022-10-21
- 2022-10-22
- 2022-10-23
- 2022-10-24
- 2022-10-31
- 2022-11-07
- 2022-11-14
- 2022-11-21
- 2022-11-28
- 2023-01-16
- 2023-04-17
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-02-20 | Pfizer-BioNTech | |
| 2 | 2021-03-13 | Pfizer-BioNTech | |
| 3 | 2021-10-02 | Pfizer-BioNTech | No |
| 4 | 2022-10-17 | Pfizer-BioNTech | Flu |
Free text
None.
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
No MedDRA codes.